Delving into the Latest Updates on Santa Maria Biotherapeutics, Inc. with Synapse

概览

关联

1

项与 Santa Maria Biotherapeutics, Inc. 相关的临床试验

NCT02262455 / Completed临床1期

An Open-Label Multiple Ascending Dose Phase 1/1B Pharmacokinetic and Pharmacodynamic Study of STM 434, an Activin Type 2B Receptor Fc Fusion, Alone and in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

This is a Phase I study to test the safety, pharmacokinetics and effectiveness of STM 434 alone, or in combination with liposomal doxorubicin, in patients with ovarian cancer or other advanced solid tumors.

开始日期2014-10-01

申办/合作机构

Santa Maria Biotherapeutics, Inc.

100 项与 Santa Maria Biotherapeutics, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Santa Maria Biotherapeutics, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 Santa Maria Biotherapeutics, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Santa Maria Biotherapeutics, Inc. 相关的转化医学

登录后查看更多信息